Pulmonary Hypertension (PH) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Pulmonary hypertension (PH) is elevated lung blood pressure from various causes, distinct from systemic hypertension, affecting the entire body. There are five categorized groups of pulmonary hypertension, each linked to specific causes, necessitating varied treatments. Despite these differences, all forms of pulmonary hypertension pose serious and potentially life-threatening risks. Pulmonary hypertension (PH) is characterized as a hemodynamic state rather than a standalone diagnosis, with a resting mean pulmonary artery pressure (PAPm) of ≥ 25 mm Hg. Within this category, pulmonary arterial hypertension represents a specific subgroup defined by unique hemodynamic features. These include precapillary pulmonary hypertension, elevated pulmonary vascular resistance (PVR), PAPm ≥ 25 mm Hg, normal pulmonary arterial wedge pressure (PAWP) ≤ 15 mm Hg, and PVR >240 dyn × s × cm-5 in individuals of any age, be they children or adults. Primary causes of pulmonary hypertension often involve left heart disease and lung disease. Recognizable symptoms include escalating exercise dyspnea, bending-induced dyspnea, fatigue, exercise-induced syncope, and edema. Treatment for pulmonary hypertension is generally symptomatic and varies based on the disease type, severity, and individual patient needs.
- The average age-adjusted PH mortality rate was 7.9 per 100,000 individuals and increased by 1.9% annually.
Thelansis’s “Pulmonary Hypertension (PH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Hypertension (PH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pulmonary Hypertension (PH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pulmonary Hypertension (PH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
